|Project Title||Principal Investigator||Institution|
|Validation study of atypical dynamic pupillary light reflex as a biomarker for autism||Yao, Gang||University of Missouri|
|The ontogeny of social visual engagement in infants at risk for autism||Klin, Ami||Yale University|
|The genetic link between autism and structural cerebellar malformations||Millen, Kathleen||University of Chicago|
|Temporal coordination of social communicative behaviors in infant siblings of children with autism||Parlade, Meaghan||University of Pittsburgh|
|Supplement to NIH ACE Network grant: "A longitudinal MRI study of infants at risk for autism"||Piven, Joseph||University of North Carolina at Chapel Hill|
|Studying the biology and behavior of autism at 1-year: The Well-Baby Check-Up Approach||Pierce, Karen||University of California, San Diego|
|Social communication phenotype of ASD in the second year||Wetherby, Amy||Florida State University|
|Signatures of gene expression in autism spectrum disorders||Kunkel, Louis||Children's Hospital Boston|
|Pupil size and circadian salivary variations in autism spectrum disorder||Colombo, John||University of Kansas|
|Prospective study of infants at high risk for autism||Chawarska, Katarzyna||Yale University|
|Predicting outcome at age 5 of younger siblings of children with ASD||Malesa, Elizabeth||Vanderbilt University|
|Placental vascular tree as biomarker of autism/ASD risk||Salafia, Carolyn||Research Foundation for Mental Hygiene, Inc.|
|Oxytocin biology and the social deficits of autism spectrum disorders||Parker, Karen||Stanford University|
|Nonlinguistic vocalizations in autism: Acoustic cry analysis in early infancy||Sheinkopf, Stephen||Women and Infants Hospital of Rhode Island|
|Neurophysiological indices of risk and outcome in autism||Webb, Sara||University of Washington|
|Multiplexed suspension arrays to investigate newborn and childhood blood samples for potential immune biomarkers of autism||Vogt, Robert||Centers for Disease Control and Prevention (CDC)|
|Model diagnostic lab for infants at risk for autism||Klin, Ami||Yale University|
|Mitochondria and autism||Wallace, Douglas; Gargus, Jay; Golomb, Beatrice; Haas, Richard; Naviaux, Robert; Barshop, Bruce||University of California, Irvine; University of California, San Diego|
|Misregulation of BDNF in autism spectrum disorders||Hempstead, Barbara||Weill Cornell Medical College|
|Metabolic biomarkers of autism: Predictive potential and genetic susceptibility||James, Sandra||Arkansas Children's Hospital Research Institute|
|Language development and outcome in children with autism (supplement)||Naigles, Letitia||University of Connecticut|
|Language development and outcome in children with autism||Naigles, Letitia||University of Connecticut|
|Infants at risk of autism: A longitudinal study (supplement)||Ozonoff, Sally||University of California, Davis|
|Infants at risk of autism: A longitudinal study||Ozonoff, Sally||University of California, Davis|
|Identifying gastrointestinal (GI) conditions in children with autism spectrum disorders (ASD)||Winter, Harland||Harvard Medical School|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Identify behavioral and biological markers that separately, or in combination, accurately identify, before age 2, one or more subtypes of children at risk for developing ASD, and evaluate whether these risk markers or profiles can improve early identification through heightened developmental monitoring and screening by 2014.
IACC Recommended Budget: $33,300,000 over 5 years
|1.L.A. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 40 projects have been supported in this area, but most projects are still in the discovery phase. Identifying reliable early biomarkers has been challenging, but some progress has been made. More work is needed to achieve the full intent of the objective.
Remaining Gaps, Needs, and Opportunities: Remaining research needs include continued discovery of biomarkers, linking biomarkers to treatment response, validation of biomarkers discovered in high risk populations for applicability in the general population, and evaluation of whether these biomarkers translate to improvement in screening and diagnosis real-world settings. There is also a need for biomarkers that are cost-effective.